LC-MS/MS Method for the Estimation of Paliperidone in Human Plasma

References

• Zhu, H.J., Wang, J.S., Markowitz, J.S., Donovan, J.L., Gibson, B.B., DeVane, C.L. (2007). Risperidone and paliperidone inhibit p-glycoprotein activity in vitro. Neuropsychopharmacology. 32: 757–764.
   Google Scholar
• Kane, J., Canas, F., Kramer, M., Ford, L., Gassmann-Mayer, C., Lim, P., Eerdekens, M. (2007). Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial. Schizophr. Res. 90: 147–161.
   Google Scholar
• Fowler, J.A., Bettinger, T.L., Argo, T.R. (2008). Paliperidone extended release tablets for the acute and maintenance treatment of schizophrenia. Clin. Ther. 30: 231–248.
   Google Scholar
• Vermeir, M., Naessens, I., Remmerie, B., Mannens, G., Hendrickx, J., Sterkens, P., Talluri, K., Boom, S., Eerdekens, M., van Osselaer, N., Cleton, A. (2008). Absorption metabolism and excretion of paliperidone a new monoaminergic antagonist in humans. Drug Metab. Dispos. 36: 769–779.
   Google Scholar
• Cletonm, A., Rossenu, S., Vermeulen, A., Cleton, A., Talluri, K., Mertens, A., Janssens, L., Boom, S. (2006). A pharmacokinetic model to document the interconversion between Paliperi-done’s enantiomers. Clin. Pharmacol. Ther. 79(2): P55–P55.
   Google Scholar
• Green, B. (2009). Paliperidone: A clinical review. Current Drug Therapy. 4(1): 7–11.
   Google Scholar
• Mannens, G., Huang, M.L., Meuldermans, W., et al. (1993). Absorption metabolism and excretion of risperidone in humans. Drug Metab. Dispos. 21: 1134–1341.
   Google Scholar
• Kramer, M., Kushner, S., Vijapurkar, U., Lim, P., and Eerdekens, M. (2007). Delaying symptom recurrence in patients with schizophrenia with paliperidone extended-release tablets: an international, randomized, double-blind, placebo-controlled study. J. Clin. Psychopharmacol. 27: 6–14.
   Google Scholar
• Karlsson, P., Hargarter, L., Dencker, E., Nyber, S., Mannaert, E., Boom, S., Talluri, K., Rossenu, S., Eriksson, B., Eerdekens, M., Farde, L. (2007). Pharmacokinetics and dopa-mine D2 and serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects: two open-label single-dose studies (PA-115). Pharmacopsychiatry. 40–A106.
   Google Scholar
• Fang, J., Bourin, M., and Baker, G.B. (1999). Metabolism of risperidone to 9-hydroxyris-peridone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch. Pharmacol. 359: 147–151.
   Google Scholar
• Megens, A.A.H.P., Awouters, F.H.L. (1994). In vivo pharmacologic profile of 9-hydroxyris-peridone the major metabolite of the novel antipsychotic risperidone. Drug Dev. Res. 33: 399–412.
   Google Scholar
• Woestenborghs, R., Lorreyne, W., Van Rompaey, F., et al. (1992). Determination of risperi-done and 9-hydroxyrisperidone in plasma, urine and animal tissues by highperformance liquid chromatography. J. Chromatogr. 583: 223–230.
   Google Scholar
• Le Moing, J.P., Edouard, S., Levron, J.C. (1993). Determination of risperidone and 9-hydroxy-risperidone in human plasma by high-performance liquid chromatography with electrochemical detection. J. Chromatogr. 614: 333–339.
   Google Scholar
• Avenoso, A., Facciola, G., Salemi, M., et al. (2000). Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reversed-phase liquid chromatography with ultraviolet detection. J. Chromatogr. B Biomed. Sci. Appl. 746: 173–181.
   Google Scholar
• Aravagiri, M., Marder, S.R., Wirshing, D., et al. (1998). Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: simultaneous determination by a high performance liquid chromatography with electrochemical detection. Pharmacopsychiatry. 31: 102–109.
   Google Scholar
• Olesen, O.V., Linnet, K. (1997). Simplified high-performance liquid chromatographic method for determination of risperidone and 9-hydroxyrisperidone in serum from patients comedicated with other psychotropic drugs. J. Chromatogr. B Biomed. Sci. Appl. 698: 209–216.
   Google Scholar
• Kousoulos, C., Dotsikas, Y., Loukas, Y.L. (2007). Turbulent flow and ternary column-switching on-line clean-up system for high throughput quantification of risperidone and its main metabolite in plasma by LC-MS/MS: application to a bioequivalence study. Talanta. 72: 360–367.
   Google Scholar
• Remmerie, B.M.M., Sips, L.L.A., de Vries, R., et al. (2003). Validated method for the determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 783: 461–472.
   Google Scholar
• Hongming, Chen., Longshan, Z. et al. (2014). Development and validation of a rapid and sensitive UHPLC–MS/MS method for the determination of paliperidone in beagle dog plasma. Asian J. Pharma Sci. 9(5): 286–292.
   Google Scholar
• Malgorzata, S., Joanna, SO., Dorota, L., Katarzyna, KK. (2011). LC–MS–MS Method for the Analysis of New Non-Imidazole Histamine H3 Receptor Antagonist 1-[3-(4-tert-Butylphenoxy) propyl] piperidine in Rat Serum-Application to Pharmacokinetic Studies. Chromatographia. 73: 913–919.
   Google Scholar
• U.S. Food and Drug Administration (2001). Bioanalytical Method Validation, Guidance for Industry. U.S. department of Health and Human Services Food and Drug Administration, Rockville, MD. http://www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf Accessed 20 September 2016.
   Google Scholar
• Das Binaya. (2013). Estimation of Gabapentin in human Plasma using LC-MS/MS method. Asian J. Pharma & Clin. Res. 6 (Suppl 3): 213–216.
   Google Scholar
• Mazahar, Farooqui., Rana, Z. Ahmed., Jaiprakash, N. Sangshetti., et al. (2013). Identification and determination of related substances of paliperidone in bulk drug and pharmaceutical formulations by HPLC and HPLC-MS-MS. Indo Amer. J. Pharma Res. 3(12): 1375–1383.
   Google Scholar